Effects of the sodium–glucose co-transporter 2 inhibitor dapagliflozin in patients with type 2 diabetes and Stages 3b–4 chronic kidney disease

Wheeler, DC; Dekkers, CCJ; Sjostrom, CD; Stefansson, BV; Cain, V; Heerspink, HJL; (2018) Effects of the sodium–glucose co-transporter 2 inhibitor dapagliflozin in patients with type 2 diabetes and Stages 3b–4 chronic kidney disease. Nephrology Dialysis Transplantation 10.1093/ndt/gfx350 . (In press). Green open access

http://ift.tt/2DWJEUI